Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1683 participants.

Also called NCT05047172

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,683 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05047172
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05047172. Randomized; quadruple masking; primary purpose prevention. Start 2022-08-02 (actual); primary completion 2027-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Acronym
CAPTIVA
Condition
Intracranial Arteriosclerosis
Condition
Stroke
Intervention (Drug)
Ticagrelor + Aspirin
Intervention (Drug)
Rivaroxaban + Aspirin
Intervention (Drug)
Clopidogrel + Aspirin
Intervention (Other)
Risk Factor Management
Lead sponsor
University of Florida (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)
Collaborator
University of Cincinnati (class: other)
Collaborator
Medical University of South Carolina (class: other)
Collaborator
Janssen Scientific Affairs, LLC (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05047172
Content hash
ee20421c5cbfcd29b0759bad33738aa28b6ceecb0d224d597fbcbc8c71ff84bb